One case of hypokalemia caused by moxifloxacin injection and literature analysis

doi:10.19803/j.1672-8629.2022.03.26

Abstract

Abstract: Objective To explore the mechanism by which hypokalemia is caused by moxifloxacin injection so as to provide reference for clinical rational and safe use of moxifloxacin. Methods The diagnosis and treatment process of one case of hypokalemia after moxifloxacin injection was analyzed. Results Symptoms of hypokalemia (2.78 mmol·L^-1) occurred one week after intravenous injection of moxifloxacin. After moxifloxacin injection was withdrawn and intravenous and oral potassium supplementation was started, the level of potassium returned to normal (4.41 mmol·L^-1). Conclusion Intravenous injection of moxifloxacin may lead to hypokalemia, which deserves more attention in clinic.

Key words: moxifloxacin, hypokalemia, adverse drug reactions

CLC Number:

R994.11

YANG Guiling, ZHAO Mudan, GAO Yiling, WANG Bei, ZHU Minghui. One case of hypokalemia caused by moxifloxacin injection and literature analysis[J]. Chinese Journal of Pharmacovigilance, 2022, 19(3): 342-344.

References

[1] Chinese Society of Respiratory Medicine. Guidelines for diagnosis and treatment of community-acquired pneumonia in Chinese adults (2016 Edition)[J]. Chinese Journal of Tuberculosis and Respiratory Medicine(中华结核和呼吸杂志), 2016, 39(4): 253-279.
[2] ZHANG TM.Observation on the efficacy of potassium chloride and sodium chloride injection in preventing drug-induced hypokalemia in the elderly[J]. Prescription Drugs in China(中国处方药), 2019, 17(2): 105-106.
[3] LIN D.Analysis of a case of hypokalemia caused by quinolones[J]. International Medical and Health Herald(国际医药卫生导报), 2011, 17(17): 2150-2151.
[4] Drug Safety Supervision Department of State Food and Drug Administration, National Center for Adverse Drug Reaction. Manual for adverse drug reaction reporting and monitoring[S] . 2012: 49.
[5] LAPI F, TUCCORI M, MOTOLA D, et al.Safety profile of the fluoroquinolones[J]. Drug Safety, 2010, 33(5): 353.
[6] XIAO DD, ZHAO GK, CHEN M.Literature analysis of 134 cases of adverse reactions caused by moxifloxacin[J]. Chinese Journal of Drug Application and Monitoring(中国药物应用与监测), 2019, 16(5): 287-291, 301.
[7] CHOI HK, JUNG JA, FUJITA T, et al.Population pharmacokinetic-pharmacodynamic analysis to compare the effect of moxifloxacin on QT interval prolongation between healthy Korean and Japanese subjects[J]. Clinical Therapeutics, 2016, 38(12): 2610-2621.
[8] FALCONE C, COMPOSTELLA L, CAMARDO A, et al.Hypokalemia during antibiotic treatment for bone and joint infections[J]. European Journal of Orthopaedic Surgery & Traumatology, 2018, 28(3): 389-395.
[9] WANG WJ, CHEN FJ.A case of hypokalemia caused by gatifloxacin[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2009, 6(10): 631-631.
[10] ALEXANDROU AJ, DUNCAN RS, SULLIVAN A, et al.Mechanism of hERG K+ channel blockade by the fluoroquinolone antibiotic moxifloxacin[J]. British Journal of Pharmacology, 2006, 147(8): 905-916.
[11] Will you have hypokalemia with ciprofloxacin—from FDA reports[EB/OL]. [2020-06-06].https://www.ehealthme.com/ds/ciprofloxacin/hypokalemia/.
[12] ZIETSE R, ZOUTENDIJK R, HOORN EJ.Fluid, electrolyte and acid-base disorders associated with antibiotic therapy[J]. Nature Reviews Nephrology, 2009, 5(4): 193-202.
[13] WU XY, TAN LN, YANG J, et al.Drug-induced hypokalemia and its clinical treatment[J]. Modern Drug Application in China(中国现代药物应用), 2009, 3(17): 200-202.
[14] WU WF, DU LY, DONG JL.Etiology and treatment progress of hypokalemia[J]. Journal of Clinical Rational Drug Use(临床合理用药杂志), 2018, 11(1): 180-181.
[15] MARIA LUKÁCS KROGAGER, CHRISTIAN TORP-PEDERSEN, RIKKE NØRMARK MORTENSEN, et al. Short-term mortality risk of serum potassium levels in hypertension: a retrospective analysis of nationwide registry data[J]. European Heart Journal, 2017, 38(2): 104-112.
[16] ABO-SALEM E, FOWLER JC, ATTARI M, et al.Antibiotic-induced cardiac arrhythmias[J]. Cardiovascular Therapeutics, 2014, 32(1): 19-25.
[17] BENNETT AC, BENNETT CL, WITHERSPOON BJ, et al.An evaluation of reports of ciprofloxacin, levofloxacin, and moxifloxacin-association neuropsychiatric toxicities, long-term disability, and aortic aneurysms/dissections disseminated by the Food and Drug Administration and the European Medicines Agency[J]. Expert Opinion on Drug Safety, 2019, 18(11): 1055-1063.
[18] TIAN CH.Thoughts on promoting adverse drug reaction monitoring in medical institutions[J]. Chinese Journal of Pharmacovigilance(中国药物警戒),2016,13(5): 272-274.